{"organizations": [], "uuid": "dc16353a5f5f1f8d50364a4a00f33db273cf1a78", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ssy-group-unit-entered-agreement-w/brief-ssy-group-unit-entered-agreement-with-zhengzhou-university-for-research-of-new-liver-fibrosis-drug-idUSFWN1QN0GY", "country": "US", "domain_rank": 408, "title": "BRIEF-Ssy Group Unit ‍Entered Agreement With Zhengzhou University For Research Of New Liver Fibrosis​ Drug", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.182, "site_type": "news", "published": "2018-03-05T20:21:00.000+02:00", "replies_count": 0, "uuid": "dc16353a5f5f1f8d50364a4a00f33db273cf1a78"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ssy-group-unit-entered-agreement-w/brief-ssy-group-unit-entered-agreement-with-zhengzhou-university-for-research-of-new-liver-fibrosis-drug-idUSFWN1QN0GY", "ord_in_thread": 0, "title": "BRIEF-Ssy Group Unit ‍Entered Agreement With Zhengzhou University For Research Of New Liver Fibrosis​ Drug", "locations": [], "entities": {"persons": [], "locations": [{"name": "zhengzhou", "sentiment": "none"}], "organizations": [{"name": "reuters) - ssy group ltd", "sentiment": "neutral"}, {"name": "brief-ssy group unit ‍entered agreement with zhengzhou university for research", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Ssy Group Ltd:\n* UNIT ‍ENTERED AGREEMENT WITH ZHENGZHOU UNIVERSITY IN RELATION TO RESEARCH AND DEVELOPMENT OF NEW DRUG USED FOR LIVER FIBROSIS​\n* ‍ AGGREGATE INVESTMENT IN RESEARCH AND DEVELOPMENT OF DRUG FOR TREATMENT OF LIVER FIBROSIS​ IS RMB 50 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T20:21:00.000+02:00", "crawled": "2018-03-06T22:19:54.015+02:00", "highlightTitle": ""}